US Stocks in Focus | Ocugen (OCGN.US) surges over 40% in pre-market trading after its COVID-19 vaccine, jointly developed with Bharat Biotech, showed 81% mid-term effectiveness.
智通财经APP获悉,3月3日(周三)美股盘前,Ocugen(OCGN.US)股价飙升,截至北京时间19:40,该股涨42.68%,报13.64美元。此前,公司宣布与印度生物技术公司Bharat Biotech共同开发的新冠病毒疫苗中期有效性为81%。